GlassScriptPhysician profile
Ramesh N Kundur
NPI 1306863063
$4,837.53
in general payments reported to CMS, 2019-2025
33 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $292 · 2021: $652 · 2022: $465 · 2023: $1,026 · 2024: $920 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.85 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $712.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $581.46 | 2019-2025 | |
| Abbott Laboratories | $546.53 | 2019-2025 | Jot Dx, Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $326.90 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $307.92 | 2019-2025 | Watchman Flx, Watchman Access System, General - Ep |
| Alnylam Pharmaceuticals INC. | $281.82 | 2023-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $264.02 | 2021-2025 | Uptravi, Opsumit |
| Amgen INC. | $188.07 | 2020-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $178.99 | 2022-2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.11 | 2019-2025 | Lifevest |
| Scpharmaceuticals INC. | $111.99 | 2023-2025 | |
| Esperion Therapeutics, INC. | $110.53 | 2020-2022 | |
| Novo Nordisk INC | $99.49 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $98.76 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $96.69 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $88.67 | 2019-2023 | |
| Astellas Pharma US INC | $77.24 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $69.27 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $66.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.41 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.27 | 2020-2024 | Wainua |
| Sanofi-Aventis U.S. LLC | $53.56 | 2022-2024 | |
| Atricure, INC. | $49.79 | 2023 | |
| Edwards Lifesciences Corporation | $49.23 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $33.62 | 2023-2024 | Xarelto |
| Daiichi Sankyo INC. | $28.95 | 2023 | Injectafer |
| Baxter Healthcare | $25.47 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $21.89 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $20.95 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Lantheus Medical Imaging, INC. | $19.46 | 2023 | Definity |
| Glaxosmithkline, LLC. | $17.75 | 2025 | Shingrix, Arexvy |
| Medtronic, INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Kundur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.